The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

gynesonics.com

Founded Year

2005

Stage

Series G | Alive

Total Raised

$278.87M

Last Raised

$32.5M | 5 mos ago

About Gynesonics

Gynesonics is a women's healthcare company focused on minimally invasive solutions for symptomatic uterine fibroids. Gynesonics has developed the Sonata System for the transcervical treatment of symptomatic uterine fibroids under intrauterine sonography guidance. The Sonata System uses radiofrequency energy to ablate fibroids under intrauterine sonography guidance. The Sonata System, including the SMART Targeting Guide, enables the operator to target fibroids and optimize ablations within them. Sonata System's design provides a straightforward, transcervical access for a uterus preserving, incision-free fibroid treatment. This intrauterine approach is designed to avoid the peritoneal cavity.

Gynesonics Headquarter Location

600 Chesapeake Drive

Redwood City, California, 94063,

United States

650-216-3860

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Gynesonics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Gynesonics in 1 CB Insights research brief, most recently on Mar 12, 2020.

Expert Collections containing Gynesonics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Gynesonics is included in 3 Expert Collections, including Women's Health & Wellness.

W

Women's Health & Wellness

1,459 items

Startups focused on providing products and services catering to women's health and wellbeing.

M

Medical Devices

11,001 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health IT

7,900 items

Gynesonics Patents

Gynesonics has filed 40 patents.

The 3 most popular patent topics include:

  • Medical equipment
  • Juniperus
  • Least concern plants
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/20/2017

3/1/2022

Surgical removal procedures, Gynaecology, Women's health, Pelvis, Gynecological surgery

Grant

Application Date

6/20/2017

Grant Date

3/1/2022

Title

Related Topics

Surgical removal procedures, Gynaecology, Women's health, Pelvis, Gynecological surgery

Status

Grant

Latest Gynesonics News

Gynesonics Names Robert Brown as Chief Financial Officer

Jan 17, 2022

Gynesonics Names Robert Brown as Chief Financial Officer New hire most recently served as president and CEO of Ximedica. Gynesonics01.17.22 Gynesonics  has named Robert Brown as chief financial officer. "I am pleased to welcome Robert to the Gynesonics team,” said Gynesonics President and CEO Christopher Owens. “Robert brings to Gynesonics a wealth of proven experience in driving scale and creating high growth strategic value. As we accelerate the commercial launch of our Sonata® System, his experience at the leadership level will play a vital role in supporting and driving our global success.”   Brown’s background includes significant experience successfully scaling business in healthcare, including medical devices. He most recently served as president and CEO for Ximedica LLC and has been active in finance roles for the past 35 years including serving as CFO of NxStage Medical Inc. , where he was an integral member contributing to the high growth revenue ramp of the organization. Prior to NxStage Medical, Brown spent more than 10 years at Boston Scientific Corporation holding leadership roles in finance supporting strategic initiatives. He also worked at United Technologies Corporation with responsibility for worldwide financial reporting, and at Deloitte and Touche in its audit and management consulting businesses. Brown is a CPA and earned an MBA in finance and international business from the University of Michigan and a bachelor of business administration in accounting from the University of Toledo. “I am excited to join the Gynesonics team,” said Brown. “The Sonata System is not only a unique and breakthrough technology, but the company’s focus on developing robust clinical data and establishing payer coverage is proving to be the correct strategy to accelerate adoption and bring this treatment to women worldwide. In the U.S. alone, over 8 million women annually avoid traditional surgical treatment for their uterine fibroid issues. I look forward to utilizing my experience to help bring Sonata to this $4 billion-plus global market.”   The Sonata System uses radiofrequency energy to ablate fibroids under real time sonography guidance from within the uterine cavity, utilizing the first and only intrauterine ultrasound transducer. The System includes a proprietary graphical user interface (SMART Guide), enabling the operator to target fibroids and optimize treatment. The Sonata System provides incision-free transcervical access for a uterus-preserving fibroid treatment. This intrauterine approach is designed to avoid the peritoneal cavity. The Sonata System is CE marked and is approved for sale in the European Union and the United States. Gynesonics is a women’s healthcare company focused on advancing women’s health, by developing minimally invasive, incision-free, uterus-preserving, transcervical technologies for diagnostic and therapeutic applications. Gynesonics has developed the Sonata System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids. Gynesonics headquarters is in Redwood City, Calif.  Related Breaking News PR Newswire 01.17.22 Michael Barbella, Managing Editor 01.14.22 Sam Brusco, Associate Editor 01.14.22 Sommetrics 01.14.22 Cleerly 01.14.22 enlightenVue Inc. 01.14.22 Endologix LLC 01.14.22 Cadence Inc. 01.13.22 Proximie 01.13.22 Sam Brusco, Associate Editor 01.13.22 PR Newswire 01.13.22 Wyss Center 01.13.22 PR Newswire 01.13.22 Sam Brusco, Associate Editor 01.13.22 GE Healthcare 01.13.22

Gynesonics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Gynesonics Rank

  • When was Gynesonics founded?

    Gynesonics was founded in 2005.

  • Where is Gynesonics's headquarters?

    Gynesonics's headquarters is located at 600 Chesapeake Drive, Redwood City.

  • What is Gynesonics's latest funding round?

    Gynesonics's latest funding round is Series G.

  • How much did Gynesonics raise?

    Gynesonics raised a total of $278.87M.

  • Who are the investors of Gynesonics?

    Investors of Gynesonics include Advanced Technology Ventures, HBM Partners, Endeavour Vision, Bain Capital, Amzak Health and 11 more.

  • Who are Gynesonics's competitors?

    Competitors of Gynesonics include Endologix, BioProtect, Monteris Medical, Aptus Endosystems, Interlace Medical and 12 more.

You May Also Like

Endologix Logo
Endologix

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.

N
Neurosonix

NeuroSonix is an Israeli medical device company targeting the market of cerebral embolic protection during cardiac surgical and other minimally invasive procedures. NeuroSonix has conceived, developed and patented a technology and medical devices for the prevention of acute cerebral embolism during open-heart cardiac surgery as well as other invasive and minimally-invasive procedures. The company's technology, which is based on ultrasound, aims to enable a non-invasive deflection of embolic material flowing inside the body, away from the cerebral arteries. This new ultrasonic modality aims to reduce the embolic load on the patient's brain. The first product developed by the company is the EmBlocker"ž, intended to provide protection from acute cerebral embolism during cardiac surgical procedures. The Protection Collar, the company's second product, is intended for embolic protection during minimally-invasive procedures and Cath-lab practice.

NeoChord Logo
NeoChord

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, received CE market clearance in December 2012.

A
Axial Biotech

Axial Biotech, founded in 2002 by a group of spine surgeons and geneticists, is focused on the use of genetics and the development of minimally invasive fusionless devices to advance the diagnosis and treatment of diseases and deformities of the human spine. Axial is a company to pursue DNA-based pre-symptomatic and prognostic tests for common spinal conditions which will augment current clinical and surgical practices. In its initial genetic product development initiative, Axial has made progress towards the discovery of a location in the human genome that is associated with adolescent idiopathic scoliosis. In addition, Axial's founders have developed five motion preserving, fusionless surgical devices (including such device currently being implanted in humans) that have the promise of expanding the current treatable scoliosis patient population by a factor of ten. Axial intends to use its genetic intellectual property in the development of bio-mechanical devices, and to apply its gene discovery/product development methodology to other spinal diseases. Axial (www.axialbiotech.com) is located in Salt Lake City, Utah.

Ecochlor Logo
Ecochlor

Ecochlor develops ballast water treatment systems that have been designed to safely and economically eliminate the worldwide transfer of aquatic invasive species and human pathogens such as cholera, in ship ballast water.

I
Intersect Partners

Intersect Partners is a California based medical devices company. The company primarily produces intragastric balloons, stent-like neurological medical devices, and associated minimally invasive drug delivery and device systems.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.